Home > Market > Market Stats >  Glaxosmithkline Pharmaceutical

Glaxosmithkline Pharmaceutical

Sector: Biotechnology & Drugs
Powered by
1424.30 -21.35 (-1.48%)
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y

Price Range

Today’s Low 1412.0
Today’s High 1459.6
52 Week Low 1372.8
52 Week High 1842.56

Key Metrics

  • Market Cap (In Cr) 24509.67
  • Beta 0.56
  • Div. Yield (%) 2.07
  • P/B 9.2
  • TTM P/E 62.48
  • Peg Ratio -0.23
  • Sector P/E 24.66
  • D/E -
  • Open Price 1429.6
  • Prev Close 1445.65
View All Metrics on Mint Genie

Analysis

Price Analysis
  • 1 Week
    2.03%
  • 3 Months
    0.37%
  • 6 Month
    -9.7%
  • YTD
    -14.32%
  • 1 Year
    1.41%
Risk Meter
  • 16% Low risk
  • 16% Moderate risk
  • 16% Balanced Risk
  • 16% High risk
  • 16% Extreme risk
Recos
7 Analysts
  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Analysts' Views
  • Ratings
  • Current
  • Strong Sell
  • 0
  • Sell
  • 2
  • Hold
  • 2
  • Buy
  • 1
  • Strong Buy
  • 2

Financials

  • INCOME
  • BALANCE SHEET
  • Cashflow
  • Period
  • 2022
  • Total Revenue
  • 3278.03
  • Selling/ General/ Admin Expenses Total
  • 981.81
  • Depreciation/ Amortization
  • 68.04
  • Other Operating Expenses Total
  • 47.06
  • Total Operating Expense
  • 2599.03
  • Operating Income
  • 679
  • Net Income Before Taxes
  • 779.05
  • Net Income
  • 1694.72
  • Diluted Normalized EPS
  • 22.13
  • Period
  • 2021
  • Total Revenue
  • 2925.6
  • Selling/ General/ Admin Expenses Total
  • 890.82
  • Depreciation/ Amortization
  • 78.46
  • Other Operating Expenses Total
  • 68.58
  • Total Operating Expense
  • 2580.44
  • Operating Income
  • 345.16
  • Net Income Before Taxes
  • 453.99
  • Net Income
  • 358.15
  • Diluted Normalized EPS
  • 23.41
  • Period
  • 2020
  • Total Revenue
  • 3224.38
  • Selling/ General/ Admin Expenses Total
  • 1059.87
  • Depreciation/ Amortization
  • 82.53
  • Other Operating Expenses Total
  • 60.16
  • Total Operating Expense
  • 3525.74
  • Operating Income
  • -301.36
  • Net Income Before Taxes
  • 305.75
  • Net Income
  • 93.2
  • Diluted Normalized EPS
  • 19.51
  • Period
  • 2019
  • Total Revenue
  • 3128.12
  • Selling/ General/ Admin Expenses Total
  • 975.25
  • Depreciation/ Amortization
  • 48.45
  • Other Operating Expenses Total
  • 66.52
  • Total Operating Expense
  • 2591.14
  • Operating Income
  • 536.98
  • Net Income Before Taxes
  • 682.67
  • Net Income
  • 445.39
  • Diluted Normalized EPS
  • 25.13
  • Period
  • 2018
  • Total Revenue
  • 2895.65
  • Selling/ General/ Admin Expenses Total
  • 934.04
  • Depreciation/ Amortization
  • 37.73
  • Other Operating Expenses Total
  • 61.82
  • Total Operating Expense
  • 2418.22
  • Operating Income
  • 477.43
  • Net Income Before Taxes
  • 539.97
  • Net Income
  • 350.73
  • Diluted Normalized EPS
  • 20.11
  • Period
  • 2017
  • Total Revenue
  • 2999.99
  • Selling/ General/ Admin Expenses Total
  • 879.36
  • Depreciation/ Amortization
  • 25.71
  • Other Operating Expenses Total
  • 93.63
  • Total Operating Expense
  • 2602.91
  • Operating Income
  • 397.08
  • Net Income Before Taxes
  • 511.19
  • Net Income
  • 336.81
  • Diluted Normalized EPS
  • 18.09
View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue
Returns Metrics (In Cr) ROA Vs ROE

Technical

Moving Average SMA
  • 5 Day1408.63
  • 10 Day1409.54
  • 20 Day1416.55
  • 50 Day1436.38
  • 100 Day1451.34
  • 300 Day1515.01

Peers

  • Price
  • Ratio
  • Name
  • Latest Price
  • Change
  • % Change
  • 52W High
  • 52W Low
  • Mkt. Cap
  • Lupin
  • 679.6
  • 25.6
  • 3.91
  • 979.25
  • 583.05
  • 29772.09

Corporate Actions

  • Board Meeting
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
  • Meeting Date
  • Purpose
  • 25-Jul-22
  • Quarterly Results
  • 16-May-22
  • Audited Results & Dividend
  • 07-Feb-22
  • Quarterly Results
  • 29-Oct-21
  • Quarterly Results
  • 26-Jul-21
  • Quarterly Results
  • 18-May-21
  • Audited Results & Dividend
  • 05-Feb-21
  • Quarterly Results

Company Profile

ABOUT Glaxosmithkline Pharmaceutical

  • Industry Biotechnology & Drugs
  • ISIN INE159A01016
  • BSE Code 500660
  • NSE Code GLAXO

GlaxoSmithKline Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the business of manufacturing, distributing, and trading in pharmaceuticals. It manufactures medicinal substances used in the manufacture of pharmaceuticals, such as antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts, and esters; glycosides and vegetable alkaloids, and chemically pure sugar. It offers a range of prescription medicines, vaccines, and consumer healthcare products. Its medicine portfolio includes Adartrel, Bactroban, Combodart, and Duodart. Its vaccines portfolio includes Ambirix, Cervarix, Fendrix, and Havrix. The Company’s products include Betamethasone, Potassium Clavulanate with Amoxycillin and Pneumococcal Polysaccharide and Conjugate Vaccine. Its oral health products include Sensodyne, parodontax and Polident. Its manufacturing unit is located at Nashik.

MANAGEMENT

  • Juby Chandy Chief Financial Officer, Whole Time Director
  • S. Dheri Executive Vice President - Vaccines
  • Ajay Nadkarni Vice President - Administration, Real Estate and Company Secretary
  • Sridhar Venkatesh Managing Director, Executive Director

Company Summary

GLAXOSMITHKLINE PHARMACEUTICAL SUMMARY

Glaxosmithkline Pharmaceutical is trading 1.48% lower at Rs 1424.30 as compared to its last closing price. Glaxosmithkline Pharmaceutical has been trading in the price range of 1459.6 & 1412.0. Glaxosmithkline Pharmaceutical has given -14.32% in this year & 2.03% in the last 5 days.

 

Glaxosmithkline Pharmaceutical has TTM P/E ratio 62.48 as compared to the sector P/E of 24.66. There are 7 analysts who have initiated coverage on Glaxosmithkline Pharmaceutical. There are 2 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.

 

The company posted a net profit of 119.28 Crores in its last quarter.

 

Listed peers of Glaxosmithkline Pharmaceutical include Lupin (3.91%), Laurus Labs (1.24%), Glaxosmithkline Pharmaceutical (-1.48%) etc.

FAQs about Glaxosmithkline Pharmaceutical

Glaxosmithkline Pharmaceutical is trading at 1424.30 as on 30 Sep, 2022 3:45:55 PM. This is -1.48% lower as compared to its previous closing price of 1445.65
The market capitalization of Glaxosmithkline Pharmaceutical is 24509.67 Cr as on 30 Sep, 2022 3:45:55 PM.
The average broker rating on Glaxosmithkline Pharmaceutical is Buy. The breakup of analyst rating is given below -
  • 0 analysts have given a strong sell rating
  • 2 analysts have given a sell rating
  • 2 analysts have given a hold rating
  • 1 analysts have given a buy rating
  • 2 analysts have given a strong buy rating
The 52 wk high for Glaxosmithkline Pharmaceutical is 1842.56 whereas the 52 wk low is 1372.8
Glaxosmithkline Pharmaceutical can be analyzed on the following key metrics -
  • TTM P/E: 62.48
  • Sector P/E: 24.66
  • Dividend Yield: 2.07%
  • D/E ratio: -
Glaxosmithkline Pharmaceutical reported a net profit of 1694.72 Cr in 2022.

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout